This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friedman, H. S. Articles by Bigner, D. D. Search for Related Content PubMed PubMed Citation Articles by Friedman, H. S. Articles by Bigner, D. D.

Chemotherapy and Radiation Therapy of Human Medulloblastoma in Athymic Nude Mice¹

Department of Pediatrics [H. S. F.], Medicine [S. C. S.], and Pathology [S. C. S., D. D. B.], Duke University Medical Center, Durham 27710, and Division of Radiation Therapy, University of North Carolina at Chapel Hill, Chapel Hill 27514 [M. V.], North Carolina

The human medulloblastoma cell line TE-671 was grown s.c. and intracranially in athymic nude mice. Tumor-bearing animals treated with chemotherapeutic agents or radiation were compared to untreated tumor-bearing controls. Tumors growing s.c. were sensitive to cyclophosphamide and vincristine with growth delays in duplicate trials of 15.8/16.5 and 12.9/15.0 days, respectively. These tumors were minimally responsive to the 2,5-bis(1-aziridinyl-3,6-dioxodiethyl ester of 1,4-cyclohexadiene-1.4-dicarbamic acid (NSC 182986) and cis-diamminedichloroplatinum II and unresponsive to methotrexate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine (NSC 351521), 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC 409962), and procarbazine. Radiation therapy with 2500 or 1500 rads as a single fraction produced a marked response, with growth delays of 39.5 and 21.1 days, respectively. Cyclophosphamide produced a significant (p < 0.0005) increase in the median survival of mice with intracranial tumors. Vincristine produced a minimal increase in the median survival while no response was seen to the 2,5-bis(1-aziridinyl-3,6-dioxodiethylester of (1,4-cyclohexadiene-1,4-dicarbamic acid at the dose level and schedule tested. This model system will allow further analysis of the therapeutic sensitivity of human medulloblastoma to other agents or combinedmodality regimens.

¹ This work was supported by Grant CA11898, Grant CA32672, American Cancer Society Grant CH-191, NINCDS NS-16974, and NIH Training Grant 5T32 AG 00007.

² To whom requests for reprints should be addressed, at Department of Pediatrics, Division Hematology-Oncology, Duke University Medical Center, Durham, N. C. 27710.

Received 11/24/82. Accepted 3/29/83.

This article has been cited by other articles:

				Q. Shu, B. Antalffy, J. M. F. Su, A. Adesina, C.-N. Ou, T. Pietsch, S. M. Blaney, C. C. Lau, and X.-N. Li Valproic Acid Prolongs Survival Time of Severe Combined Immunodeficient Mice Bearing Intracerebellar Orthotopic Medulloblastoma Xenografts Clin. Cancer Res., August 1, 2006; 12(15): 4687 - 4694. [Abstract] [Full Text] [PDF]